Evidence map›Paper›PMID 32975478›Full record

ArticleCell cycle (Georgetown, Tex.)2020

The requirement for cyclin E in c-Myc overexpressing breast cancers.

Yu Zhou, Yan Geng, Yujiao Zhang, Yubin Zhou, Chen Chu, Samanta Sharma, Anne Fassl, Deborah Butter, Piotr Sicinski

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Yu ZhouDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School , Boston, MA, USA.
Yan GengDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School , Boston, MA, USA.
Yujiao ZhangDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School , Boston, MA, USA.ORCID 0000-0002-8820-1602
Yubin ZhouDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School , Boston, MA, USA.
Chen ChuDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School , Boston, MA, USA.ORCID 0000-0001-8084-0867
Samanta SharmaDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School , Boston, MA, USA.
Anne FasslDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School , Boston, MA, USA.
Deborah ButterDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School , Boston, MA, USA.
Piotr SicinskiDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical School , Boston, MA, USA.
Harvard University · US

Funding

Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI MYLES A BROWN · 2013 to 2026
$30.1M
Targeting intratumor heterogeneity in breast cancerR35CA197623 · NCI · DANA-FARBER CANCER INST · PI KORNELIA POLYAK · 2015 to 2026
$12.4M
Novel functions of D-type and E-type cyclins in normal and in cancer cellsR01CA202634 · NCI · DANA-FARBER CANCER INST · PI SICINSKI, PETER · 2016 to 2020
$2.1M
Functions of Cyclin/CDK complexes in development and cancerR50CA243769 · NCI · DANA-FARBER CANCER INST · PI GENG, YAN · 2019 to 2023
$898k
NCI NIH HHS P50 CA168504NCI NIH HHS R01 CA202634NCI NIH HHS R35 CA197623NCI NIH HHS R50 CA243769
6 · The paper itself

Abstract

Basal-like triple-negative breast cancers frequently express high levels of c-Myc. This oncoprotein signals to the core cell cycle machinery by impinging on cyclin E. High levels of E-type cyclins (E1 and E2) are often seen in human triple-negative breast tumors. In the current study, we examined the requirement for E-type cyclins in the c-Myc-driven mouse model of breast cancer (MMTV-c-Myc mice). To do so, we crossed cyclin E1- (E1

Indexed as

AnimalsCell CycleCell DivisionCell Line, TumorCell ProliferationCyclin-Dependent Kinase 2Cyclin EFemaleGene Expression Regulation, NeoplasticHumansMiceProto-Oncogene Proteins c-mycTriple Negative Breast NeoplasmsCyclin-Dependent Kinase 2Cyclin EMYC protein, humanProto-Oncogene Proteins c-mycbreast cancerc-Myccyclin E

Identifiers

PMID32975478
PMCPMC7644156
OpenAlexW3088795248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.